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1. Introduction 
The definition and classification of the cardiomyopathies has been traditionally a complex 
and quite variable subject. In 2006, the American Heart Association issued a scientific 
statement elaborated by a task force of experts that contemplated the important 
development of molecular genetics in recent years, to explain the etiology of the diseases of 
cardiac muscle, or cardiomyopathies, previously considered idiopathic (B.J. Maron et al., 
2006a). The document stated that “Cardiomyopathies  are an heterogeneous group of 
myocardial diseases associated with mechanical and/or electrical dysfunction that usually, 
but not always, exhibit inappropriate ventricular hypertrophy or dilation, and  are 
originated by a variety of causes, frequently genetic. Cardiomyopathies involve just the 
heart or are part of systemic disorders that often lead to cardiovascular death or heart failure 
related disability”. Myocardial damage secondary to coronary atherosclerosis, heart valve 
disease, congenital heart disease, and systemic hypertension, is excluded from this 
definition. Primary or metastatic cardiac tumors and diseases primarily affecting the 
endocardium with minimal or absent myocardial damage neither are included. The 
document also discourages the use of the classical terminologies hypertrophic, dilated, and 
restrictive cardiomyopathies because they have overlapping features and often mutate from 
one type to another during the course of the disease. Cardiomyopathies are then classified 
into 2 groups, primary when there is only heart involvement, and secondary if the heart is 
affected by systemic diseases with multiorganic involvement. (Table 1) Primary 
cardiomyopathies are divided into genetic, acquired, and mixed (genetic and acquired).  
 
GENETIC MIXED ACQUIRED 
Hypertrophic Dilated Inflammatory 
Arrhythmogenic Right Ventricular Restrictive Tako-tsubo 
Noncompaction  Peripartum 
Glycogen Storage  Tachycardia-induced 
Mitochondrial  Infants of diabetic mothers 
Conduction Defects   
Ion Channelopathies   
Table 1. Classification of the primary cardiomyopathies (modified from B.J. Maron, et al., 
2006a). 
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A salient feature of this classification is the inclusion of ion channelopathies caused by gene 
coding mutations of Na, K, and Ca channels. These channelopathies may result in deadly 
ventricular arrhythmias and can only be identified by molecular genetic studies since no 
structural cardiac damage is objectified. The Brugada syndrome, the long and short QT 
syndromes, the cathecolaminergic polymorphic ventricular tachycardia, and the 
unexplained nocturnal sudden death in Southeastern Asian youngsters belong to the 
channelopathies. Some conduction disorders are also included in the classification. 
In contrast with the American Heart Association point of view, the European Society of 
Cardiology issued a report in the year 2008 with an updated definition and classification of 
the cardiomyopathies (Elliot et al., 2008). (Table 2) It was there stated that 
“Cardiomyopathies are structural and functional myocardial diseases in the absence of 
systemic hypertension, coronary atherosclerosis, valvulopathies, or congenital heart disease 
sufficient to explain the observed abnormality”.  Therefore, hypertrophic cardiomyopathy was 
defined as “Increased ventricular thickness or mass in the absence of loading conditions 
sufficient to cause the observed abnormality”. This definition better reflects the terminology 
used in pediatrics (Elliot et al., 2008; Franklin et al., 1999). With regard to the classification, it 
was based on the identification of phenotypes according to their structural and functional 
features recognizing the following cardiomyopathies: hypertrophic, dilated, restrictive, 
arrhythmogenic right ventricular, and unclassified (Colan et al., 2007). Every phenotype could be 
familial or non-familial emphasizing the role of genetics in some cardiomyopathies and 
orienting the etiologic diagnosis. The differentiation between primary and secondary 
cardiomyopathy is then abandoned. Left ventricular non-compaction and the takotsubo 
cardiomyopathy are included in the group of unclassified cardiomyopathies. The European 
Society of Cardiology experts do not believe that channelopathies and conduction disorders 
should be considered as cardiomyopathies. In our opinion, the European Society of 
Cardiology classification is more user-friendly for general physicians. 
 
 
  CARDIOMYOPATHIES   
HCM DCM ARVC RCM Unclassified 
 
FAMILIAL/ GENETIC  
NON-
FAMILIAL/ 
NON- 
GENETIC 
Unidentified 
gene defect 
Disease sub-
type 
 Idiopathic 
Disease sub-
type 
 
HCM: hypertrophic cardiomyopathy, DCM: dilated cardiomyopathy, ARVC: arrhythmogenic right 
ventricular cardiomyopathy, RCM: restrictive cardiomyopathy. 
Table 2. European Society of Cardiology classification of primary cardiomyopathies 
(modified from Elliot, et al., 2008). 
2. Classification 
Though hypertrophic cardiomyopathy was first recognized by Liouville in France in 1869, 
(Liouville, 1869, as cited in Marian, 2007), it was not until the 1950’s that was rediscovered in 
Britain by Brock and Teare (Brock & Fleming, 1956; Teare, 1958).  Initial reports emphasized 
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the presence of left ventricular outflow tract obstruction until it was realized that this could 
be absent (B. J. Maron et al, 2009). Since then, two main types of hypertrophic  
cardiomyopathy were distinguished, with or without obstruction. Nowadays, we know that 
hypertrophic cardiomyopathy, is the most frequent monogenic disorder in cardiology and 
the commonest cause of sudden death in youngsters in either form of presentation (J. 
Seidman & C. Seidman, 2001). 
Regardless of the presence or absence of obstruction, hypertrophic cardiomyopathy is 
classified into two main groups, familial and non-familial. (Table 3) The latter comprises 4 
subgroups: hypertrophic cardiomyopathy associated with obesity, infants born to diabetic 
mothers, athlete’s heart, and amyloidosis. This chapter will mainly address the familial forms of 
hypertrophic cardiomyopathy also composed of 4 subgroups: sarcomeric,  and 3 others in 
association with malformation syndromes, inborn errors of metabolism, and  neuromuscular 
disorders (Elliot et al., 2008). The sarcomeric forms are the most frequent and have an 
autosomal dominant inheritance. They are caused by missence mutations of genes encoding 
the contractile proteins of the sarcomere. A mutation involves the change of a DNA base for 
another resulting in the replacement of an aminoacid in a polypeptide for another. Though 
readable, the meaning (sense) of the genetic message is changed. Considerable genetic and 
phenotypic heterogeneity is found in hypertrophic cardiomyopathy. In other words, 
different gene mutations may cause similar phenotypes or on the contrary, the same gene 
may result in dissimilar ones. The presence of modifying genes, like that encoding 
angiotensin II, environmental influences, gender, and associated conditions might explain 
some of these dissimilarities (Alcalai et al., 2008). About 20 genes carrying a great number of 
mutations have already been identified in hypertrophic cardiomyopathy (Kim et al., 2011). 
(Table 4) However, just 3 of them, beta-myosin heavy chain (MYH7), myosin binding 
protein C (MYBPC3), and troponin T (TNNT2) are responsible for almost 75% of the cases, 
thence, the remaining are rare. The genes involved in pediatric hypertrophic 
cardiomyopathy have a similar frequency and distribution as in adult patients (Kaski et al., 
2009). 
 
FAMILIAL  NON-FAMILIAL.
Sarcomeric  Associated with obesity
Associated with  malformation syndromes Infants born to diabetic mothers 
Associated with  inborn errors of metabolism Athlete’s heart
Associated with neuromuscular disorders Amyloidosis
Table 3. Classification of the hypertrophic cardiomyopathies (modified from Elliot et al., 
2008). 
It has been suggested that the genotype might have an influence in the prognosis in 
hypertrophic cardiomyopathy. Patients with MYH7 mutation would have more severe 
ventricular hypertrophy and present earlier in life, those with TNNT2 would have less left 
ventricular hypertrophy but higher risk of sudden death, and late onset of the disease and 
favorable prognosis would be found in patients with MYBPC3 mutation (Moolman et al., 
1997; Niimura et al., 1998; Watkins et al., 1992). Nevertheless, a more recent study showed 
that regardless of the gene mutation, patients with a positive molecular genetic study, had a 
higher risk of cardiovascular death, stroke, worse functional class, diastolic and systolic left 
ventricular dysfunction, and that the long term outcome was worse for patients carrying 
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more than one mutation. (Bos et al., 2009) The latter finding was not corroborated in 
children. (Kaski et al., 2009). 
 
GENE PROTEINS GENE PROTEINS 
MYH7 ǃ-Myosin heavy chain TTN Titin 
MYH6 ǂ-Myosin heavy chain LBD3 LIM binding domain 3 
MYBPC3 
Cardiac myosin binding protein 
C 
CSRP3 Muscle LIM protein 
TNNT2 Cardiac troponin T TCAP Telethonin 
TNNI3 Cardiac troponin I VCL Vinculin/metavinculin 
TNNC1 Cardiac troponin C ACTN2 ǂ-Actinin 2 
TPM1 ǂ-Tropomyosin MYOZ2 Myozenin 2 
MYL3 Myosin essential light chain JPH2 Junctophillin-2 
MYL2 Myosin regulatory light chain PLN Phospholamban 
ACTC ǂ-Cardiac actin   
Table 4. Susceptibility genes in hypertrophic cardiomyopathy (modified from Bos et al., 2009 
& Kim et al., 2011). 
3. Prevalence 
The estimated prevalence of hypertrophic cardiomyopathy in the adult population as 
assessed by echocardiographic screening is 1:500 (B.J. Maron et al., 1995a). However, in 
pediatrics, the observed prevalence is much lower because hypertrophic cardiomyopathy 
usually has late gene expression. Large population registries from Australia and the US 
show a prevalence varying between 0.47 and 1.24:100,000 inhabitants and an occurrence of 
nearly 25% among all types of cardiomyopathies (Lipschultz et al., 2003; Nugent et al., 2003). 
In our institution, the incidence of hypertrophic cardiomyopathy was 1.1% for all children 
with heart disease attending the Division of Cardiology of the Children’s Hospital (Bruno et 
al., 2002). 
4. Pathology 
4.1 Macroscopic findings 
The gross anatomy generally shows severe left ventricular hypertrophy and small cavity size. 
(Fig. 1) The hypertrophy mainly involves the ventricular septum, and for this reason, one of 
the early denominations of the disease was asymmetric septal hypertrophy (Henry et al., 1973). 
Notwithstanding, hypertrophy may occur symmetrically or affect other segments like the 
posterior wall, and the apical or middle sections of the left ventricle (Falicov & Resnekov, 1977; 
Louie & Maron, 1987; Minami et al., 2011; Yamaguchi et al., 1979). Midventricular obstructive 
hypertrophic cardiomyopathy is more frequent in Asians with a prevalence of around 10% in 
tertiary centers and carries a higher risk for adverse events (B.J. Maron et al., 2003a; Minami et 
al., 2011). Patients with apical involvement are less commonly genotype positive than those 
with the more frequent variants of the disease but the affected genes are usually the same 
frequently found in the other patients (MYBPC3 and MYH7) (Gruner et al., 2011). In infants 
and children, the right ventricle can also be involved (Biagini et al., 2005).Almost 5% of 
patients with hypertrophic cardiomyopathy evolve to end stage dilated cardiomyopathy with 
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Fig. 1. Longitudinal section of the heart of a 9 year-old boy, who died suddenly during 
ordinary activities, with predominant hypertrophy of the septum but also showing 
increased thickness of the free wall of both ventricles. During life, obstruction of both the left 
and right ventricular outflow tracts was present.  
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extensive fibrosis, myocardial wall thinning and cavity dilation (Harris et al., 2006). The left 
atrium is enlarged as a consequence of the elevated left ventricular end diastolic pressure 
caused by diastolic dysfunction and mitral regurgitation secondary to left ventricular outflow 
tract obstruction or associated mitral valve anomalies (Klues et al., 1992). The physiopathology 
of mitral insufficiency in hypertrophic obstructive cardiomyopathy was initially attributed to 
the Venturi effect produced by systolic flow acceleration in the left ventricular outflow tract 
dragging the anterior mitral valve leaflet towards the ventricular septum causing both 
obstruction and insufficiency (Grigg et al., 1992; Panza et al., 1992; Shah et al., 1969 & 1971). A 
subsequent echocardiographic and Doppler study suggested instead, that the mitral valve 
leaflets are protruding into a narrow left ventricular outflow tract at the onset of ejection 
causing that rapid forward flow becomes the dominant force that pushes the leaflets toward 
the septum being the immediate cause of obstruction. After the onset of obstruction the leaflets 
are forced against the septum by the pressure difference across the orifice. The raising gradient 
leads to a smaller orifice and a higher gradient (Sherrid et al., 1993). The systolic anterior 
motion of the mitral leaflets precludes the proper sealing of the mitral orifice generating mild 
to moderate mitral regurgitation (M. Maron et al., 2011). The mitral valve in these patients 
shows alterations in size and shape which are thought to be primary abnormalities of the 
disease. The main changes are elongation and increase of the leaflet area usually not 
symmetrical. The size of the left ventricular outflow, the hyperdynamic contraction and the 
alterations of the mitral valve are the causes of the obstruction. 
4.2 Microscopy 
The distinct feature of the microscopic examination of the myocardium is hypertrophy and 
marked disarray (greater than 5% of the myocardial tissue) of individual and grouped 
myocardiocytes (myofibers) that instead of being normally aligned are interspersed in 
different directions forming whorls around areas of fibrosis. Cells and fibers lose their normal 
parallelism and can even be found almost perpendicular to each other. (Fig. 2) The disarray 
also includes the intracellular myofibrils.  Other findings include increased connective tissue 
leading to interstitial fibrosis and thickening of the microvascular coronary artery walls with 
luminal reduction resulting in ischemia and fibrosis (Ferrans et al., 1972). Fibrosis and scar 
replacement of necrosed cells is more evident in areas with greater hypertrophy. Initially, it 
was postulated that the mechanism for the disarray and hypertrophy was caused by the 
increased effort of the myocytes to compensate the inefficient contractility of the affected 
sarcomere proteins. This would activate the insulin and tissue growth factors and angiotensin 
II resulting in the myocardial changes (J. Seidman & C. Seidman, 2001). Further experimental 
animal investigations and studies of hypertrophic cardiomyopathy mutations in man, by the 
same authors, found instead that the mutated sarcomeres had in fact increased function. It was 
then hypothesized that they would activate signals for hypertrophic remodeling. 
Abnormalities in calcium signaling were encountered leading to necrosis and replacement 
fibrosis producing diastolic dysfunction, a main feature of hypertrophic cardiomyopathy (C. 
Seidman & J. Seidman, 2011). An investigation by the same group, also found that a profibrotic 
marker like serum procollagen is significantly higher in patients with full blown hypertrophic 
cardiomyopathy and mutation carriers, with a still not developed phenotype, than in controls, 
pointing to increase collagen synthesis and fibrosis. Late gadolinium enhancement studies are 
positive when hypertrophy is already present (Ho et al., 2010). The myocardial disarray, 
interstitial fibrosis, and ischemia are also the substrate for the occurrence of arrhythmias. 
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4.3 Phenocopies 
Patients with nonsarcomeric hypertrophic cardiomyopathy are considered to be 
phenocopies (Table 5), and might have the same pathologic findings as has been reported in 
some malformation syndromes or neuromuscular disorders like Noonan’s syndrome and 
Friedreich’s ataxia (Burch et al., 1992; Kawai et al., 2000).  However, this is not the case for 
inborn errors of metabolism like glycogen storage disease where the gross anatomy resembles 
hypertrophic cardiomyopathy but microscopic examination shows the glycogen deposits in 
the myocytes without disarray. (Fig. 3) It should be noted that the present definition of 
phenocopy, according to the Webster’s New World Medical Dictionary in its second 
acception is: “A person who has an environmental condition that mimics a condition that is 
produced by a gene”. Since the examples just mentioned are genetic in origin, the term 
phenocopy could be inappropriate but is how these entities have been named for a long 
time.   
 
 
 
 
 
 
 
 
 
Fig. 2. Microscopic view of the myocardium with the typical disarray of hypertrophic 
cardiomyopathy in an infant who died in congestive heart failure. Myofibers have lost the 
usual parallel disposition and describe whorls around areas of fibrosis. The disarray is 
present in the myofibers, among myocytes and in the myofibrils within the myocytes. 
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Fig. 3. Typical lacework appearance of the myocardium in a patient with type II Pompe’s 
disease. There is normal alignment of the vacuolated myocardial fibers with glycogen 
storage. 
 
GENE PROTEIN SYNDROME 
TAZ Tafazzin (G4.5) Barth syndrome/LVNC 
DTNA ǂ-dystrobrevin Barth syndrome/LVNC 
LAMP2 
Lysosome-associated membrane 
protein 2 
Danon’s syndrome/WPW 
GLA ǂ-galactosidase  Fabry’s disease 
AGL Amylo-1,6-glucosidase Forbes disease 
FXN Frataxin Friedreich’s ataxia 
PTPN11 
Protein tyrosine  phosphatase. 
nonreceptor type 11, SHP-2 
Noonan’s syndrome, LEOPARD 
syndrome 
RAF1 
V-RAF-1 murine leukemia viral 
oncogene homolog 1 
Noonan’s syndrome, LEOPARD 
syndrome 
KRAS 
v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
Noonan’s syndrome 
SOS1 Son of sevenless homolog 1 Noonan’s syndrome 
GAA ǂ-1,4-glucosidase deficiency Pompe’s disease 
PRKAG2 AMP-activated protein kinase WPW/HCM 
LVNC: left ventricular noncompaction, WPW: Wolff-Parkinson-White, HCM: hypertrophic 
cardiomyopathy. 
Table 5. Genes involved in the production of phenocopies (modified from Bos et al., 2009).  
www.intechopen.com
 Hypertrophic Cardiomyopathy in Infants and Children 
 
41 
5. Clinical findings 
Aside from the genetic and phenotypic heterogeneity already mentioned  in hypertrophic 
cardiomyopathy, the age, form of presentation, and outcome, are also quite diverse. The 
age of the patient at presentation is a determinant of prognosis (Colan et al., 2007). 
Newborn and infants are more likely to be referred for congestive heart failure while 
older children are usually asymptomatic at the time of diagnosis and the consultation is 
requested because of the presence of a heart murmur, cardiomegaly casually detected on a 
chest x-ray, or electrocardiographic abnormalities (Bruno et al., 2002).  Initially, 
asymptomatic patients may go on without symptoms for a long period of time until they 
begin experiencing fatigue and dyspnea, and less frequently, palpitations, chest pain, and 
syncope or sudden death which might be the first symptom ever. Another cause of 
referral is the investigation of cardiac involvement in patients with conditions known to 
be associated with hypertrophic cardiomyopathy like the malformation syndromes, inborn 
errors of metabolism or neuromuscular disorders. However, in other circumstances, the 
associated disease may have been unnoticed and the cardiomyopathy is discovered first. 
The presence of physical findings suggesting an association then prompts referral to the 
geneticist (Alday & Moreyra, 1984). With regard to the physical examination itself, in 
hypertrophic obstructive cardiomyopathy, the peripheral pulses may rise and descend 
rapidly. When considerable cardiac enlargement  is present, a precordial bulge and 
outward displacement of the point of maximal impulse are usually found. A double apical 
impulse caused by a 4th heart sound is often noted. A harsh, blowing systolic murmur 
with varying intensity, related to the degree of obstruction and mitral regurgitation, can 
be listened along the left sternal border and at the apex. A distinctive feature of these 
murmurs is the variability seen with maneuvers that increase or reduce the obstruction 
intensifying or decreasing their intensity (Moreyra et al, 1972). (Fig. 4) Patients with non 
obstructive hypertrophic cardiomyopathy may also have ejection systolic murmurs along 
the left sternal border though softer than when there is left ventricular outflow 
obstruction. An ambulatory electrocardiographic study performed in infants, children and 
adolescents with hypertrophic cardiomyopathy concluded that arrhythmias occur rarely 
before adolescence. However, from then on, prevalence of nonsustained ventricular 
tachycardia is as high as 18%. It is also worth mentioning that absence of arrhythmias is 
not synonymous of low risk for sudden death (McKenna et al., 1988).  Supraventricular 
and ventricular tachycardias may be equally found. Atrial fibrillation may occur in end-
stage dilated hypertrophic cardiomyopathy (Harris et al., 2006). Very rarely, patients with 
hypertrophic cardiomyopathy have associated Wolff-Parkinson-White syndrome 
(Bockowski et al., 2007). The development of high rate supraventricular tachycardias is 
poorly tolerated in these patients with left ventricular diastolic dysfunction. This might 
lead to syncope and sudden death which are the most feared complications of 
hypertrophic cardiomyopathy. Several mechanisms have been reported as a cause of 
syncope like tachyarrhythmias, left ventricular outflow tract obstruction, systemic 
hypotension, and 3rd degree AV block. Sudden unexpected death may be the first and 
only symptom in hypertrophic cardiomyopathy and this is the most frequent cause of 
death in young athletes during competition. However, sudden death also occurs during 
usual activities, at rest, or during sleep time. The estimated rate of sudden death in 
children is 3% per year, a similar figure to that found in adults cared for in tertiary centers 
(Bruno & al., 2002; B.J. Maron et al., 1982; McKenna & Deanfield, 1984). Heart failure in 
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this disease is usually provoked by diastolic dysfunction secondary to left ventricular 
hypertrophy, myocyte disarray and fibrosis. The presence of outflow obstruction is an 
additional factor leading to heart failure. In 3 to 5 % of patients the end stage is reached 
and systolic failure associated with left ventricular wall thinning and increased 
ventricular volume become a serious indication of poor prognosis (Biagini et al., 2005 & 
Harris et al., 2006). 
 
 
Fig. 4. Simultaneous hemodynamic recordings of the left ventricular inflow (LV in), aorta 
(Ao) and main pulmonary artery (MPA). An electrocardiogram (ECG) and a 
phonocardiogram (phono) were also recorded. There is a small basal  gradient between the 
left ventricular inflow and the aorta which increases in a post-extrasystolic beat together 
with the intensity of the systolic murmur shown in the phonocardiogram, as a consequence 
of the stronger contraction following the post-extrasystolic pause. (IHSS: idiopathic 
hypertrophic subaortic stenosis). 
6. Laboratory studies 
6.1 Radiology 
The chest x-ray is usually normal in early stages of the disease but following the pubertal 
growth spurt shows cardiomegaly at the expense of the left sided chambers (B.J. Maron et 
al., 1986). (Fig. 5) The same is true for patients evolving to end-stage hypertrophic 
cardiomyopathy (Biagini et al., 2005). Finally, infants with severe heart failure nearly always 
have considerable cardiac enlargement at presentation. Pulmonary venous hypertension 
secondary to elevation of the left ventricular end diastolic pressure is reflected by the well 
known resultant pulmonary vascular changes. 
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6.2 Electrocardiography and allied techniques  
The electrocardiogram is usually abnormal in almost all patients with hypertrophic 
cardiomyopathy. (Panza & Maron, 1989) The electrocardiographic abnormality, even a 
slight one, may precede the echocardiographic findings showing left ventricular 
hypertrophy in family members carrying the genotype of probands with hypertrophic 
cardiomyopathy. Therefore, this should be kept on mind when screening relatives of 
hypertrophic cardiomyopathy patients (Gregor et al., 1989). Left atrial enlargement and 
left ventricular hypertrophy by voltage criteria usually associated with ST-T 
abnormalities are seen. (Fig. 6) Younger patients may have combined ventricular or 
isolated right ventricular hypertrophy with a rightwards QRS axis. (Fig. 7) Another 
frequent finding is the presence of pathological deep and narrow Q waves. An R + S sum 
higher than 10 mV on the limb leads of the electrocardiogram has been recently 
proposed as a risk factor for sudden death in children with hypertrophic 
cardiomyopathy (Ostman-Smith et al., 2005). (Fig. 8)  An electrocardiographic Wolff-
Parkinson-White pattern or syndrome is very rare in patients with sarcomeric 
hypertrophic cardiomyopathy. However, it has been described in mutations of genes like 
those encoding AMP-activated protein kinase (PRKAG2) and lysosome associated 
membrane protein 2 (LAMP2) producing glycogen storage disease and Danon disease 
respectively. Both of them recognized as phenocopies of hypertrophic cardiomyopathy 
(Alday et al., 2010). Ambulatory electrocardiography and exercise testing are used for 
arrhythmia detection and risk stratification in older children with hypertrophic 
cardiomyopathy. The presence of nonsustained ventricular tachycardia by Holter 
monitoring or an abnormal blood pressure response to exercise are considered risk 
factors for sudden death (Elliot et al., 2000). 
 
 
 
 
 
Fig. 5. Chest x-rays of a boy at 11 and 13 years of age showing great increase in the heart size 
coincident with pubertal growth spurt.  
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Fig. 6. Electrocardiogram of a 16 year-old male patient showing increased R wave voltages 
and secondary ST-T changes indicating severe left ventricular hypertrophy. 
 
 
 
Fig. 7. Electrocardiogram belonging to a 4 year-old boy with a QRS axis of -120º with Q 
waves in leads II, III and aVF. There are signs of combined ventricular hypertrophy, loss of 
R wave voltage from V4 to V8 with appearance of QS complexes in V6 and pathological Q 
waves in V7 and V8. 
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Fig. 8. Electrocardiogram of a 14 year-old male patient with a vertical QRS axis (+120º) and 
voltage criteria for left ventricular hypertrophy. A limb lead voltage sum > 10 mV is 
considered a risk factor for sudden death in children. 
6.3 Echocardiography  
Echocardiography associated with color flow Doppler is the most effective test for the 
diagnosis of hypertrophic cardiomyopathy (B.J. Maron et al., 2003a). It allows detection of 
the disease, follow-up of progression, and risk stratification for sudden death (B.J. Maron et 
al., 1986, Ostman-Smith et al., 2005). The wall thickness echocardiographic criteria for the 
diagnosis of hypertrophic cardiomyopathy  was set at greater than 2 SD above the mean for 
the body surface area of the population for a localized or general myocardial hypertrophy 
(Grenier et al., 2000). When in the absence of pulmonary valve stenosis the right ventricular 
wall thickness exceeds 4 mm the right ventricle is considered to be involved too (Nugent et 
al., 2005). Left ventricular hypertrophy is most frequently asymmetric with greater 
involvement of the interventricular septum than the rest of the walls, though it can also be 
concentric. (Fig. 9 - 11) More rarely, it is localized in the anterior wall, the apex, or in the mid 
left ventricle (M. Maron et al., 2009, Minami et al., 2011). The mid ventricular obstruction 
may lead to the development of an apical left ventricular aneurysm. (Fig. 12) In younger 
children the right ventricle may also be affected (Biagini et al., 2005). As a consequence of 
mitral insufficiency and/or diastolic dysfunction, there is left atrial enlargement. The 
systolic anterior movement of the mitral valve contacting the ventricular septum that causes 
left ventricular outflow tract obstruction in patients with hypertrophic obstructive 
cardiomyopathy is readily seen (B.J. Maron et al., 2003). Color flow mapping allows 
detection of the site of obstruction. (Fig. 13) The gradient across the outflow tract is 
estimated by continuous wave Doppler that also allows assessment of the mitral 
regurgitation severity. (Fig. 14) Transesophageal echocardiography is more sensitive than 
transthoracic studies for evaluation of primary mitral valve anomalies producing mitral 
incompetence (Kuhl & Hanrath, 2004). The presence of left ventricular outflow tract 
obstruction is now considered a risk factor for adverse events in hypertrophic 
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cardiomyopathy (M. Maron et al., 2003). Furthermore, we now know that almost 70% of 
patients with hypertrophic cardiomyopathy have gradients across the left ventricular 
outflow considering the obstruction caused by exercise, when studied with stress echo. 
Actually, it should be performed in all patients with no significant gradient at rest (M. 
Maron et al., 2006). Estimation of diastolic dysfunction in hypertrophic cardiomyopathy is 
performed by studying the pulmonary vein and transmitral Doppler flow tracings but since 
they depend on loading conditions are not reliable to predict adverse outcomes in children 
with hypertrophic cardiomyopathy (McMahon et al., 2004). Tissue Doppler velocities 
measurements at the mitral annulus level are more sensitive in detecting diastolic 
dysfunction allowing early diagnosis in hypertrophic cardiomyopathy genetic carriers 
before they develop hypertrophy (Nagheb et al., 2003). (Fig. 15) Tissue Doppler studies can 
also  predict adverse events like death, ventricular tachycardia, cardiac arrest, and exercise 
intolerance in affected children with the disease (McMahon et al., 2004). 
 
 
 
 
 
 
Fig. 9. Four-chamber bidimensional echocardiographic view of a 16 year-old asymptomatic 
male patient with hypertrophic cardiomyopathy with asymmetric septal hypertrophy. The 
septum and the posterior wall measure 21 mm and 9.5 mm respectively. 
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Fig. 10. Bidimensional echocardiogram showing long (A) and short (B) axis parasternal 
views of the left ventricle of a 22 year-old female followed since early childhood with severe 
asymmetrical hypertrophy of the septum measuring 31 mm in diameter. There is convexity 
toward the left ventricular cavity. The mitral leaflets initiate an anterior motion to provoke 
mitral septal contact and the resultant left ventricular outflow tract obstruction. The left 
atrium is mildly enlarged. The tip of a catheter for DDD pacing is seen in the right 
ventricular cavity (arrows). 
 
 
Fig. 11. Bidimensional  echocardiographic long axis view with massive septal hypertrophy 
(38 mm) in a girl with a strong family history (2 siblings). Courtesy Dr Ricardo Pignatelli, 
Texas Children’s Hospital. 
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Fig. 12. Bidimensional echocardiographic view of a patient with midventricular obstruction. 
The left ventricle has an upper inflow (*) and a lower apical chamber (#) as a result of the 
obstruction. Courtesy Dr Ricardo Pignatelli, Texas Children’s Hospital. 
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Fig. 13. Echocardiographic 4-chamber view of asymmetric septal hypertrophy with left 
ventricular outflow tract flow acceleration (arrow) by color Doppler. (AMV: anterior mitral 
valve). Courtesy Dr Ricardo Pignatelli, Texas Children’s Hospital. 
 
 
Fig. 14. Continuous wave Doppler showing a severe gradient (87.6 mmHg) across the left 
ventricular outflow tract in the same patient shown on figure 10. 
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Fig. 15. Decreased Doppler tissue septal velocities (<5cm/second) in a patient with massive 
hypertrophic cardiomyopathy. Courtesy Dr Ricardo Pignatelli, Texas Children’s Hospital. 
6.4 Computed tomography and magnetic resonance imaging  
Cardiac computed tomography and magnetic resonance imaging yield superior anatomic 
data than echocardiography since they allow better definition of the anterolateral wall and 
tip of the left ventricle and the right ventricle. However, these procedures are more costly 
and the former exposes the patient to radiation (M. Maron et al., 2009). (Fig. 16 ) 
Nevertheless, they are very useful when thoracic deformities prevent satisfactory cardiac 
visualization by transthoracic echocardiography. Cardiovascular magnetic resonance has 
also demonstrated that mitral leaflet elongation is present in hypertrophic cardiomyopathy 
independently of other phenotypic variants indicating that the mitral abnormalities are 
primary, thus, their important role in the pathophysiology of the left ventricular outflow 
obstruction (M. Maron, et al.; 2011). On the other hand, gadolinium magnetic resonance 
imaging late enhancement allows detection of the amount of myocardial fibrosis and is a 
predictor of systolic dysfunction (M. Maron et al., 2008). A more recent study reports that is 
also effective for prognostication of adverse outcomes and which patients might require a 
cardioverter-defibrillator (Fig. 17) (Bruder et al., 2010). 
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Fig. 16. A. Long axis view of a cardiac magnetic resonance image of a 5 year-old 
asymptomatic boy with severe hypertrophic cardiomyopathy. B:  Magnetic resonance 
imaging of a short axis projection of the heart of a 3 year-old boy with severe heart failure.  
(IVS: interventricular septum, LV: left ventricle, PW: posterior wall, RV: right ventricle). 
Courtesy Dr Ricardo Pignatelli, Texas Children’s Hospital. 
 
 
 
Fig. 17. A.Cardiac magnetic resonance image of the heart of a patient with positive delayed 
gadolinium enhancement indicating a diffuse pattern of fibrosis (arrowheads). B: Long axis 
view of a cardiac magnetic resonance image of the heart of a 9 year-old boy with a localized 
delayed gadolinium enhancement image in the interventricular septum (arrow).  Courtesy 
Dr Ricardo Pignatelli, Texas Children’s Hospital. 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
52
6.5 Cardiac catheterization and cineangiocardiography 
We owe to cardiac catheterization and cineangiocardiography the initial understanding of 
the physiopathology of hypertrophic cardiomyopathy shortly after its rediscovery about 
half a century ago (Braunwald et al., 1964; Wigle, Auger & Marquis, 1967). These techniques 
were then considered the gold standard for the diagnosis of hypertrophic obstructive 
cardiomyopathy. (Fig. 18) With the advent of the just discussed noninvasive imaging 
techniques like Doppler-echocardiography, computed tomography, and magnetic resonance 
imaging, this invasive procedure is no longer necessary for diagnostic purposes. Nowadays, 
this method is only used before planned surgical treatment or percutaneous interventions 
for septal reduction. 
 
 
Fig. 18. A. Left ventricular cineangiocardiogram  in the right anterior oblique projection 
showing a hypertrophied chamber with subaortic obstruction and moderate mitral 
insufficiency with left atrial enlargement. B. In the left anterior oblique view the anterior 
mitral valve can be seen contacting the septum. LV: left ventricle; LA: left atrium; MV: mitral 
valve.  
7. Complications 
7.1 Sudden death and congestive heart failure 
The main complications in children with hypertrophic cardiomyopathy are syncope and 
sudden unexpected death. The latter may be the first and only manifestation of the disease 
and is considered to be secondary to ventricular tachycardia and fibrillation caused by 
myocardial fibrosis and ischemia (Basso et al., 2000; B.J. Maron et al., 2000b). Sudden death 
occurs more often in older children with hypertrophic cardiomyopathy either during 
strenuous sport activities or at rest but is infrequent in infants (B.J. Maron et al., 2003a) who 
are more prone to present and die with  congestive heart failure specially in  secondary 
forms (Bruno et al., 2002). 
7.2 Arrhythmias 
Supraventricular and nonsustained ventricular tachycardias, were found in almost a third of 
pediatric and adolescent patients with hypertrophic cardiomyopathy studied by ambulatory 
electrocardiography (McKenna, et al., 1988). However, their outcome after a mean follow-up 
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of 3 years was rather benign. In a study from our group, a quarter of the patients had 
symptomatic atrial or ventricular tachycardia. Three out of 7 died suddenly during follow-
up (Bruno et al., 2002). Rarely, 3rd degree atrioventricular block is found in children with 
hypertrophic cardiomyopathy. They could present with near syncope or syncopal attacks as 
the 1st manifestation of the disease (Rosen et al., 1997). 
7.3 Evolving phenotype 
Children with hypertrophic cardiomyopathy may evolve to dilated or restrictive 
cardiomyopathy phenotypes in 5% of the cases. In both circumstances they have a dimmer 
prognosis and become candidates for heart transplantation (Biagini et al., 2005; Denfield et 
al., 1997; Shirani et al., 1993). 
7.4 Infectious endocarditis  
Bacterial endocarditis is an uncommon complication in hypertrophic cardiomyopathy 
though can occur affecting the left ventricular aspect of the anterior mitral valve leaflet, 
especially in the presence of obstruction (Aoun et al., 1994; Morgan-Hughes & Motwani, 
2002). Antibiotic prophylaxis for infectious endocarditis is then recommended. 
7.5 Stroke  
Ischemic stroke is somewhat frequent and a cause of death in adult hypertrophic 
cardiomyopathy but has not been mentioned in children (B.J. Maron et al., 2000a). 
8. Differential diagnosis 
The most important differential diagnosis is with the athlete’s heart and is sometimes 
somewhat difficult to make. Highly trained competitive athletes may have 
electrocardiographic abnormalities that resemble those of hypertrophic cardiomyopathy. 
As in this situation, the left ventricle is hypertrophied but the wall thickness as 
determined by echocardiography does not exceed 15 mm in diameter and the 
hypertrophy is symmetrical. The left ventricular cavity is dilated and the ejection fraction 
is normal while hypertrophic cardiomyopathy is frequently accompanied by unusual 
distribution of hypertrophy,  the left ventricle is smaller in size (<4.5 cm) and the ejection 
fraction is higher than normal. Furthermore, left ventricular diastolic function is normal in 
young athletes but is always impaired in hypertrophic cardiomyopathy (B.J. Maron, 
Spirito & Pelliccia, 1995b). Tissue Doppler studies has also been very useful to distinguish 
those patients in the “grey zone” (Cardim et al., 2003). When still in doubt regarding the 
diagnosis, cessation of physical activities usually results in regression of the left 
ventricular mass in a few weeks’ time (B.J. Maron et al.., 1993). Genetic screening might be 
useful when they are positive for a mutation which occurs in up to 70% of patients with 
hypertrophic cardiomyopathy. On the contrary, a negative test does not exclude the 
possibility of a mutation still not discovered.  
9. Phenocopies and associations 
A recent large epidemiologic study of the pediatric population with hypertrophic 
cardiomyopathy established that almost a quarter of patients with unexplained left 
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ventricular hypertrophy do not have a sarcomeric etiology (Colan et al., 2007). These 
variants are called phenocopies and are listed in Table 5. They are classified as malformation 
syndromes, inborn errors of metabolism, and neuromuscular disorders and each group numbers 
about one third of the total. 
9.1 Malformation syndromes 
9.1.1 Noonan’s and LEOPARD syndromes  
The most common malformation syndromes associated with hypertrophic cardiomyopathy 
included in the European Society of Cardiology classification of familial hypertrophic 
cardiomyopathy, are Noonan’s syndrome and its allelic variant LEOPARD syndrome, 
acronym for lentiginosis, electrocardiographic anomalies, ocular hypertelorism, pulmonic 
stenosis, abnormal male genitalia, retardation of growth, and deafness.  The prevalence of 
Noonan,s syndrome, initially described as the Turner phenotype with normal karyotype 
(Noonan,  1968), is estimated in 1:2,000 births (Nora et al., 1974). (Fig. 19)  It is inherited as 
an autosomic dominant form and nearly 80% have congenital heart disease, most frequently 
pulmonic valve and arterial stenoses, and atrial and ventricular septal defects. The 
introduction of echocardiography as a diagnostic tool, allowed the recognition of an 
association with hypertrophic cardiomyopathy in almost a quarter of patients (Nora et al., 
(1975). In the Australian epidemiologic study of childhood cardiomyopathies, 28% of 80 
patients with hypertrophic cardiomyopathy had Noonan’s syndrome (Nugent et al., 2005). 
These patients presented earlier and had more frequent biventricular involvement. 
However, they did not find greater adverse events rate than in sarcomeric hypertrophic 
cardiomyopathy.  In about 40-50% of patients a mutation of protein tyrosine phosphatase 
nonreceptor type 11 (PTPN11) is found (Type 1 Noonan’s syndrome), but this is present in 
90% of LEOPARD patients (Sznajer et al., 2007; Tartaglia et al., 2001). This gene controls a 
series of developmental processes, among them the genesis of semilunar valves. The 
mutation is then mainly present in patients with heart defects but not in those with 
hypertrophic cardiomyopathy. 
9.1.2 Related conditions 
Some related genetic conditions to Noonan’s syndrome like the Costello syndrome, the 
cardiofaciocutaneous syndrome, and palmo-plantar hyperkeratosis with woolly hair may 
also be associated with hypertrophic cardiomyopathy (Peirone et al., 2005, Roberts et al., 
2006). 
9.2 Inborn errors of metabolism 
9.2.1 Pompe’s disease  
Pompe’s disease or type II glycogen storage disease is an autosomal recessive inherited 
disorder caused by absence of the acid alpha-glucosidase enzyme (GAA) preventing the 
normal degradation of glycogen in the cardiac myocyte (Hers, 1963). There is an infantile 
type with massive cardiac enlargement as seen in hypertrophic cardiomyopathy with 
obstruction leading to congestive heart failure and early death (Ehlers et al., 1962). A typical 
electrocardiogram is shown in Fig. 20. Late onset Pompe’s disease with a better outcome has 
also been described (Winkle et al., 2005). Enzyme replacement therapy is now available for 
treatment of GAA deficiency. 
www.intechopen.com
 Hypertrophic Cardiomyopathy in Infants and Children 
 
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19. A. Phenotype of a 10-year-old girl with Noonan’s syndrome and hypertrophic 
cardiomyopathy. There is short stature, peculiar face, eyelid ptosis with downward slant, 
ocular and mammillar hypertelorism, low set ears, pterigium colli, and a prominent chest. B. 
Ten-year-old girl with LEOPARD syndrome. The multiple lentigines and hypertrophic 
obstructive cardiomyopathy became apparent long after she had been operated on for 
severe pulmonary valve stenosis when she was 6-month old (Reproduced with permission 
from Am Heart J, 1984; Vol.108, pp. 996-1000).  
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Fig. 20. Typical electrocardiogram of an infant with Pompe’s disease. There is short 
atrioventricular conduction and biventricular hypertrophy with large voltages and no 
repolarization abnormalities.  
9.2.2 Other glycogen storage diseases 
A genetic study of 75 patients with hypertrophic cardiomyopathy found that 3 out of 35 
patients with negative sarcomere protein mutations had genetical defects in lysosome-
associated membrane protein 2 (LAMP2) responsible for the X-linked disorder   Danon’s 
disease/Wolff-Parkinson-White in 2 of the 3, and in AMP-activated protein kinase gamma 2 
(PRKAG2) in the remaining, causing Wolff-Parkinson-White/hypertrophic cardiomyopathy 
(Arad et al., 2005). Both conditions produce glycogen storage and might wrongly be 
considered as sarcomeric hypertrophic cardiomyopathies. The presence of preexcitation 
should point to the correct diagnosis. Type IIIa and IV glycogen storage diseases are very 
rare conditions caused by deficiencies in debrancher and branching enzymes respectively. 
These patients have muscular hypotonia with elevated creatine kinase and heart and liver 
involvement. There is heterogenous severity of the disease and the hypertrophic 
cardiomyopathy is concentric. The inheritance is autosomal recessive (Kishnani et al., 2010). 
(Fig. 21) 
9.2.3 Fabry’s disease  
Fabry’s disease, an X-linked disorder characterized by intracellular accumulation of 
glycosphingolipids caused by deficiency of the lysosomal enzyme alpha-galactoside A 
(GLA) may result in late onset hypertrophic cardiomyopathy, therefore it is rare in children. 
The reported prevalences in adult males and females with hypertrophic cardiomyopathy are 
7.5 and 12% respectively (Chimenti et al., 2004; Sachdev et al., 2002). Enzyme replacement 
therapy for these patients is available (Eng et al., 2001).  
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Fig. 21. Short and long axis parasternal echocardiographic views of the heart of a 19-year-
old female with type III glycogen storage disease with concentric hypertrophic 
cardiomyopathy.  
9.3 Neuromuscular disorders 
Friedreich’s ataxia is an autosomic recessive hereditary disorder with spinocerebellar 
degeneration and frequently associated with hypertrophic cardiomyopathy (Gottdiener et 
al., 1982). A mutation of the frataxin gene (FXN) alters the energy production through 
mitochondrial iron dysmetabolism resulting in mitochondrial damage producing muscle 
fiber fibrosis (Michael et al., 2006). The cardiomyopathy may precede the neurological 
manifestations (Alday & Moreyra, 1984). 
9.4 Association with congenital heart disease 
Not infrequently, hypertrophic cardiomyopathy and congenital heart disease are associated 
in children (Somerville & Becu, 1978). In most circumstances the defects are not severe. 
Ventricular and atrial septal defects and pulmonary valve stenosis have been reported, the 
last two mainly in patients with Noonan’s and LEOPARD syndromes (Bruno et al., 2002; 
Tikanoja et al., 1999). However, associations with severe conditions like tetralogy of Fallot 
and atrioventricular septal defect have also been found (Alday et al., 1985; Eidem et al., 
2000). (Fig. 22)  
9.5 Association with left ventricular noncompaction 
Left ventricular noncompaction belongs to the category of unclassified cardiomyopathies . It 
is characterized by the presence of prominent myocardial trabeculations and sinusoid tracts 
mainly in the left ventricle. (Fig. 23) Affected patients frequently develop a dilated 
cardiomyopathy with heart failure, arrhythmias, and systemic thromboembolism. Recent 
molecular studies have shown that mutations of genes producing phenocopies like Barth 
syndrome, or even dilated and hypertrophic cardiomyopathies, are present in patients with 
left ventricular noncompaction. We recently reported a family with overlapping phenotypes 
for left ventricular noncompaction, hypertrophic cardiomyopathy, and Wolff- Parkinson-
White syndrome. We could not obtain genetic molecular studies but on the basis of features 
shared with affected patients suspected a mutation of either PRKG2 and LAMP-2 which 
cause hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome or Danon’s 
disease respectively (Alday et al., 2010). 
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Fig. 22. Two dimensional echocardiogram (A) and left ventricular cineangiography (B) in a 
patient with tetralogy of Fallot six months after a right modified Blalock-Taussig shunt 
showing severe ventricular septal hypertrophy, a hypoplastic left ventricle and a dilated 
aorta overriding a ventricular septal defect.  
 
 
Fig. 23. A and B. Echocardiographic four-chamber view of two sisters followed since infancy 
showing hypertrophic cardiomyopathy and associated left ventricular noncompaction. The 
arrow in A points deep sinusoid tracts. LV: left ventricle, LA: left atrium.  
10. Treatment 
The treatment of hypertrophic cardiomyopathy aims to improve the quality of life alleviating 
symptoms and to stratify the risk for sudden death to prevent it from happening. Several 
algorrhythms have been proposed, a slightly modified  one is shown in Fig. 24 (Berger et al., 
2009). These authors emphasize the existing difficulties to implement prospective  controlled 
randomized trials to define the benefits of different treatment options for this population, 
therefore most current therapies are empirical or the result of consensus.  In older children 
intensive physical exercise is contraindicated. The disease presenting early has a severe 
prognosis this being the reason for indicating medical treatment even in asymptomatic 
children (Bruno et al., 2002). Patients who are symptomatic should receive pharmacological 
treatment with adrenergic beta blockers which do not decrease the basal outflow gradient but 
are able to prevent its accentuation in situations of exacerbated inotropism of the heart. 
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Fig. 24. Algorithm for the treatment of hypertrophic cardiomyopathy (Modified from 
Berger, et al. (2009) Cardiol Young, Vol.19, pp. 66-73).  
 Beta blockers also have anti-ischemic properties which increase ventricular filling by 
decreasing the heart rate. In these patients, calcium channel blockers like verapamil can be 
an alternative to beta blockers. It is not recommended to use them together. In patients with 
severe gradients and  pulmonary hypertension are not advised because of the danger of 
precipitating acute pulmonary edema. If there is no improvement,  disopyramide, which is 
an antiarrhythmic drug with negative inotropic effects, is able to decrease basal gradients. 
The combination of disopyramide and beta blockers has been used succesfully in adults but 
there is no reported experience in children (Sherrid et al., (2005). For very symptomatic 
smaller children, in spite of full medical treatment, permanent DDD pacing with short 
atrioventricular interval to favor the consistent capture of the right ventricle has been used 
to lower the left ventricular outflow tract obstruction by changing the pattern of left 
ventricular activation (Alday et al., 1998 & Fananapazir et al., 1992). DDD pacing is a 
reasonable alternative to surgery in symptomatic children despite pharmacological 
treatment if they are still too young for surgery, taking into account that the approach to an 
extended septal myectomy is just the aortic valve with a small annulus at this age. A very 
recent study has also shown progressive relief of symptoms and gradient reduction at long 
term follow-up (Galve et al., 2010). However, as with other types of treatment, DDD pacing 
does not protect against the possibility of sudden arrhythmic death (Bruno et al., 2002). The 
gold standard for the treatment of hypertrophic obstructive cardiomyopathy is still the 
surgical septal myomectomy (B.J. Maron et al., 2003a; Stone et al., 1993). In experienced 
centers the mortality is very low and the abolition of the gradient is instantaneous and 
persistent. The remaining obstruction is usually negligible. These excellent hemodynamic 
results are associated with improvement of symptoms. The results have been followed for 
many years and the need for repeat procedures is rare. It should be remembered that the 
child has to be old enough to permit the transaortic approach to the septum  (Berger et al., 
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2009). For this reason, reoperation might be necessary in children 14-year-old or younger 
(Minakata et al., 2005). With regard to catheter septal ablation with alcohol or 
radiofrequency the 2003 Expert Consensus Document on Hypertrophic Cardiomyopathy, 
addressing alcohol septal ablation, states that until the long-term effects of the myocardial 
scar are known, the procedure is not advised in children  (Jensen et al., 2011; B.J. Maron et 
al., 2003a; Sigwart 1995) In patients with symptomatic hypertrophic nonobstructive 
cardiomyopathy, calcium antagonists like verapamil could be used to improve the diastolic 
performance of the left ventricle. Beta blockers are also indicated in this form of the disease. 
Recently the use of perhexiline which is a metabolic modulator has been introduced for the 
treatment of patients with this phenotype with improvement of the diastolic performance of 
the left ventricle and of symptoms (Abozguia et al.; 2010). This was a preliminary report that 
has still to be supported by further investigations. Infants with heart failure and older 
children with evolution to a dilated cardiomyopathy should be treated with drugs usually 
employed for treatment of systolic heart failure. These cases may eventually need heart 
transplantation (Shirani et al., 1993). 
11. Prevention 
Risk stratification of sudden death in infants and children differs from what is done in 
adults. In children, cardiac death occurs infrequently and non sudden cardiac death is as 
common as sudden arrhythmic death. The main risk factors  for sudden death in children 
with hypertrophic cardiomyopathy are, according to Maron et al., previous cardiac arrest, 
syncope, or sustained ventricular tachycardia, family history of sudden death, frequent 
repetitive non sustained ventricular tachycardia, abnormal blood pressure response to 
exercise, end-stage hypertrophic cardiomyopathy, and massive left ventricular hypertrophy 
(B.J. Maron et al., 2003b). Other criteria for death prognostication proposed more recently, 
specifically in children, take into account the electrocardiographic voltage and 
echocardiographic parameters like the septal thickness and the left ventricular wall/left 
ventricular diastolic dimension ratio (Ostman-Smith et al., 2005). For non-sudden cardiac 
death, massive left ventricular hypertrophy and abnormal blood pressure response to 
exercise are considered significant risk factors for mortality (Decker et al., 2009). Sudden 
cardiac death due to hypertrophic cardiomyopathy occurs mostly in adolescence and early 
adulthood and very infrequently before 10 years of age. These cases are due to ventricular 
tachycardia or ventricular fibrillation. In fact, hypertrophic cardiomyopathy is the most 
common cause of sudden death in the young including athletes (J. Seidman & C. Seidman, 
2001). This is the reason why the diagnosis of hypertrophic cardiomyopathy at this age is a 
strong indication to discontinue the practice of competitive sports. At this time it seems that 
to establish a prognosis by the knowledge of the specific disease causing mutation is not 
reasonable for the individual patient. Implantable cardioverter defibrillators are effective to 
prevent arrhythmic sudden death but in infants and children are indicated mainly in 
secondary prevention (B.J. Maron, et al., 2000b; Epstein, A.; et al., 2008). The cardioverter 
defibrillator implantation is plagued with complications in children, this being the reason 
for the reluctance of its use in primary prevention (Berul et al., 2008). In a nonrandomized 
controlled trial amiodarone was at one time reported to improve survival in hypertrophic 
cardiomyopathy associated with ventricular tachycardia (McKenna et al., 1985). However, 
the frequent toxic effects of amiodarone might counteract its benefits (Berger et al., 2009).  It 
then could be concluded that the properly functioning cardioverter defibrillator is 
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nowadays the only effective treatment for the prevention of sudden arrhythmic death (B.J. 
Maron, et al., 2000b). 
12. Screening strategies 
It is well known that hypertrophic cardiomyopathy is a genetic disease of the sarcomeric 
proteins with great heterogeneity of genetic basis and fenotypic expression which does not 
only involve these structures but also include abnormalities of the connective tissue, mitral 
valve, and intramural coronary arteries. The genetic defect may be influenced by modifiers 
genes and unknown enviromental factors. The strategy for clinical screening for 
hypertrophic cardiomyopathy with 12 lead electrocardiogram and echocardiogram in non 
affected family members including < 12 year-old children, is optional, unless there is history 
of early death due to hypertrophic cardiomyopathy or other serious complications in the 
family, or is an athlete in training, or evidence of incipient left ventricular hypertrophy, or 
onset of suspicious symptoms. In family members 12 to 18 years of age, clinical follow-up 
should be performed every 12 to 18 months and from then on every 5 years. The period of 
screening should be extended to adulthood since we now know that certain mutant genes 
can provoke a disease of rather late onset (B.J. Maron et al., 2004).  
13. Conclusion 
Great strides have been made since the rediscovery of hypertrophic cardiomyopathy in the 
late 50’s last century. Important advances in the understanding of the genetics and 
physiopathology of the disease have occurred as well as development of superb imaging 
technologies. Treatment is tailored according to the phenotype and stage of the disease. The 
very important differences between adult and childhood hypertrophic cardiomyopathy 
have been underlined in this chapter hoping that will help physicians in decision making 
when dealing with these patients. 
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